logo
  

GulfMark Offshore Results Miss Estimate, Cuts FY Guidance; Stock Down 8%

GulfMark Offshore Inc (GLF) Monday reported third-quarter net earnings of $24.3 million or $0.92 per share compared with $32.3 million or $1.23 per share last year.

Excluding items, adjusted earnings for the quarter were $0.75 per share.

Revenues for the quarter were $128.7 million compared with $121.8 million in the prior year.

Analysts polled by Thomson Reuters estimated earnings of $0.82 per share on revenues of $134.3 million for the quarter. Analysts' estimates typically exclude special items.

CEO Quintin Kneen said, "The global offshore vessel market flattened in the third quarter as fewer offshore drilling rigs were utilized than anticipated... In contrast, the Southeast Asia market remained challenged as national oil companies in the region have been slow to award new contracts, compounded by an increasing supply of offshore vessels in that region."

Looking ahead to the fourth quarter, the company expects revenues of $110 million to $115 million, while analysts expect $136.5 million.

For the full year, the company projects revenues of $490 million to $495 million, down from prior guidance of $510 million to $525 million. Analysts expect revenues of $519 million.

GulfMark Offshore provides offshore marine support and transportation services primarily to companies involved in the offshore exploration and production of oil and natural gas.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT